A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major depressive disorder
文摘
Intranasal insulin did not significantly improve depressive symptomatology compared to placebo. Notwithstanding results, intranasal insulin may offer benefits in domain-based psychopathology. Improvements in stratification strategies are necessary to identify responsive subpopulations.